Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma

Cancer

Blood and Immune System

12 July 2022

Published on 12 Jul 2022
Last Updated on 12 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended listing polatuzumab vedotin on the Medication Assistance Fund (MAF) for treating patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for haematopoietic cell transplant due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness at the price proposed by the manufacturer.

Clinical indication, subsidy class and MediShield Life claim limit for polatuzumab vedotin are provided in the Annex.

Polatuzumab vedotin for treating relapsed or refractory DLBCL (12 Jul 22) [PDF, 147 KB]

Polatuzumab vedotin for treating relapsed or refractory DLBCL PES (12 Jul 22) [PDF, 128 KB]